User:Jordynlazic/Apixaban
 | This is the sandbox page where you will draft your initial Wikipedia contribution.
If you're starting a new article, you can develop it here until it's ready to go live. If you're working on improvements to an existing article, copy only one section at a time of the article to this sandbox to work on, and be sure to use an edit summary linking to the article you copied from. Do not copy over the entire article. You can find additional instructions here. Remember to save your work regularly using the "Publish page" button. (It just means 'save'; it will still be in the sandbox.) You can add bold formatting to your additions to differentiate them from existing content. |
Medical Uses
[edit]Dosing
[edit]There are different dosing regimens of Apixaban based on what is being treated and what the desired outcome is. The dosing for stroke prevention in patients with atrial fibrillation and one CHADS2 risk factor is 5 mg twice daily[1]. Treatment of deep vein thrombosis and pulmonary embolism with Apixaban is 10 mg twice daily for 7 days, then 5 mg twice daily[1]. Prophylaxis after recurrent deep vein thrombosis or pulmonary embolism and prevention of venous thromboembolism is 2.5 mg twice daily[1].
Apixaban can be taken irrespective of food[2].
Pharmacokinetics
[edit]Apixaban's half life is 12 hours[1]. The renal excretion of Apixaban is 25% and is contraindicated in those with a creatinine clearance under 15 millilitres per minute[1]. Apixaban has a bioavailability of greater than 60%[2]. Peak plasma concentrations are reached in less than 4 hours for all direct oral anticoagulants[2].
Apixaban is a substrate of cytochrome P450 3A4, and the P-glycoprotein transporter[2]. Therefore, inhibitors or inducers of CYP 3A4 enzymes or P-glycoproteins have the possibility of changing Apixaban exposure in the body[2].
Drug Interactions
[edit]Drug-Drug Interactions
[edit]The addition of Aspirin, to Apixaban therapy in patients with venous thromboembolism should be avoided as it nearly doubles bleeding rates[2].
References
[edit]- ^ a b c d e Hurst, Katherine Victoria; O’Callaghan, John Matthew; Handa, Ashok (2017-07-10). "Quick reference guide to apixaban". Vascular Health and Risk Management. 13: 263–267. doi:10.2147/VHRM.S121944. ISSN 1176-6344. PMC 5513886. PMID 28744136.
{{cite journal}}: CS1 maint: unflagged free DOI (link) - ^ a b c d e f Witt D.M., & Clark N.P., & Vazquez S.R. (2020). Venous thromboembolism. DiPiro J.T., & Yee G.C., & Posey L, & Haines S.T., & Nolin T.D., & Ellingrod V(Eds.), Pharmacotherapy: A Pathophysiologic Approach, 11e. McGraw Hill.